RUA Life Sciences (GB:RUA)
LSE:RUA
Top Page
RUA Life Sciences
(LSE:RUA)
Select Model
Select Model
Rating:56Neutral
Price Target:
13.00 p
▼(-7.14% Downside)
Action:ReiteratedDate:04/01/26
The score is primarily driven by mixed fundamentals: solid revenue growth and a relatively strong balance sheet are offset by ongoing losses and persistently negative cash flow. Technical indicators add near-term pressure due to bearish momentum, while the low P/E provides a meaningful valuation offset.
Positive Factors
Revenue growth & gross margins
The company has delivered multi-year top-line expansion while preserving strong gross profitability. Durable revenue growth plus attractive product-level margins indicate real market demand and scalable product economics, supporting eventual operating leverage if SG&A is managed.
Negative Factors
Persistent negative cash flow
The company remains cash-consuming despite narrowing losses. Persistent negative operating and free cash flow increases dependence on external capital, limits organic reinvestment capacity, and raises execution risk if access to funding tightens over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & gross margins
The company has delivered multi-year top-line expansion while preserving strong gross profitability. Durable revenue growth plus attractive product-level margins indicate real market demand and scalable product economics, supporting eventual operating leverage if SG&A is managed.
Read all positive factors
RUA Life Sciences (RUA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£8.38M
Dividend YieldN/A
Average Volume (3M)148.53K
Price to Earnings (P/E)3.6
Beta (1Y)0.28
Revenue Growth87.72%
EPS GrowthN/A
CountryUK
Employees40
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)<0.01
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)£7.16M
RUA Life Sciences Business Overview & Revenue Model
Company Description
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of med...
How the Company Makes Money
null...
RUA Life Sciences Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
72
Positive
Cash Flow
39
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.46M | 4.46M | 4.11M | 2.19M | 2.18M | 1.63M |
| Gross Profit | 3.30M | 3.06M | 3.17M | 1.72M | 1.43M | 1.04M |
| EBITDA | 272.00K | -383.33K | 401.00K | -1.57M | -1.95M | -2.04M |
| Net Income | -150.34K | -145.33K | 1.00K | -1.44M | -2.00M | -2.07M |
Balance Sheet | ||||||
| Total Assets | 9.12M | 9.12M | 9.26M | 8.17M | 5.66M | 7.63M |
| Cash, Cash Equivalents and Short-Term Investments | 3.25M | 3.25M | 3.57M | 3.93M | 1.48M | 2.96M |
| Total Debt | 1.35M | 794.00K | 1.03M | 389.00K | 475.00K | 344.00K |
| Total Liabilities | 1.93M | 1.89M | 1.86M | 987.00K | 980.00K | 1.04M |
| Stockholders Equity | 7.14M | 7.14M | 7.30M | 7.18M | 4.68M | 6.58M |
Cash Flow | ||||||
| Free Cash Flow | -323.00K | -298.00K | -281.00K | -1.38M | -1.62M | -3.27M |
| Operating Cash Flow | -162.00K | -137.00K | -219.00K | -1.33M | -1.17M | -2.36M |
| Investing Cash Flow | -59.00K | -59.00K | 70.00K | -85.00K | -449.00K | -904.00K |
| Financing Cash Flow | -459.00K | -459.00K | -196.00K | 3.89M | 132.00K | -66.00K |
RUA Life Sciences Technical Analysis
Positive
14.00
Price Trends
13.73
Negative
13.31
Positive
12.51
Positive
Market Momentum
-0.21
Negative
54.60
Neutral
56.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Positive. The current price of 14 is above the 20-day moving average (MA) of 13.21, above the 50-day MA of 13.73, and above the 200-day MA of 12.51, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 54.60 is Neutral, neither overbought nor oversold. The STOCH value of 56.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:RUA.
RUA Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £8.38M | 3.60 | 0.08% | ― | 87.72% | ― | |
52 Neutral | £19.64M | -18.39 | -69.35% | ― | 31.78% | 10.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £45.89M | 0.83 | 32.72% | ― | ― | ― | |
47 Neutral | £15.25M | -1.51 | -153.92% | ― | 90.42% | 79.21% | |
43 Neutral | £5.42M | -2.61 | -2.42% | ― | ― | ― | |
43 Neutral | £4.20M | 77.73 | -16.78% | ― | -4.98% | -114.29% |
* Healthcare Sector Average
GB:RUA
RUA Life Sciences
13.50
2.25
20.00%
GB:CREO
Creo Medical
11.13
1.32
13.52%
GB:GDR
Genedrive
0.95
-0.57
-37.58%
GB:IHC
Inspiration Healthcare
21.90
5.15
30.75%
GB:OPTI
OptiBiotix Health
5.25
-11.00
-67.69%
GB:SUN
Surgical Innovations
0.45
-0.05
-10.00%
RUA Life Sciences Corporate Events
Business Operations and StrategyShareholder Meetings
RUA Life Sciences Secures Strong Shareholder Backing at AGM
Positive
Mar 17, 2026
RUA Life Sciences announced that all resolutions proposed at its latest Annual General Meeting were duly passed by shareholders with strong majorities. The voting outcomes, which showed high levels of support and minimal opposition across all 14 r...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
RUA Life Sciences flags growth inflection as CDMO pipeline builds and heart valve deal nears
Positive
Mar 17, 2026
RUA Life Sciences reported that activity in its UK contract development and manufacturing arm remains strong, with two main manufacturing contracts underpinning revenue and a growing pipeline of development work worth about £500,000 expected ...
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
RUA Life Sciences Posts Annual Report and Sets March AGM Date
Neutral
Feb 12, 2026
RUA Life Sciences has distributed its Annual Report and Accounts together with the notice of its upcoming Annual General Meeting to shareholders, and made these documents available on its investor relations website. The AGM is scheduled to take pl...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
RUA Life Sciences Triples Revenues and Nears Profitability After Abiss Acquisition
Positive
Jan 30, 2026
RUA Life Sciences has delivered a transformational 18‑month period to 30 September 2025, more than tripling revenue to £6.7m compared with the prior 12‑month period, while sharply reducing its loss before tax to £0.2m and tur...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.